interleukin-2 complex

Interleukin-2 complex (IL-2c) refers to a cytokine-antibody complex formed by the non-covalent association of recombinant interleukin-2 (IL-2) with specific anti-IL-2 monoclonal antibodies. This approach is designed to extend the half-life of IL-2 and redirect its activity toward specific immune cell subsets by masking certain binding epitopes. In the context of cancer immunotherapy, complexes are often engineered to be "CD122-directed," meaning they favor activation of effector T cells and natural killer (NK) cells via the intermediate-affinity dimeric receptor (CD122/CD132) while sterically hindering binding to the high-affinity receptor alpha-chain (CD25). This bias aims to enhance anti-tumor immunity while minimizing the activation of immunosuppressive regulatory T cells (Tregs) and reducing systemic toxicities such as vascular leak syndrome. While primarily used as a research tool in preclinical models, the concept has paved the way for clinical-stage IL-2 fusion proteins and engineered cytokines.

Other names

IL-2/anti-IL-2 antibody complexCD122-directed IL2 therapyCD-122-directed IL2 therapyCD 122-directed IL2 therapy